Of the four companies that appealed the removal of their drugs from the UK's Cancer Drugs Fund, only Bayer successfully overturned the decision.NHS England has agreed to restore Bayer's stomach... Read more
Cognite is pleased to announce that Arun Dhillon has joined the company as an Account Director. Arun was previously with ICC Lowe (formerly Brand(x)) working out of the Zurich office and brings a wealth of account handling experience both in the UK and Europe. He will therefore be a valuable acquisition for the fast growing Strategy and Communications Boutique
The REAL WORLD Challenge: Are you maximising the effectiveness of RWE?
RWE is now recognised as critical to all commercial activities and is becoming embedded across the life-science industry.
pH Associates is hosting a summit on May 5th (4-7pm) that will take a fresh look at what a successful RWE programme looks like for all parties and challenge you to include more diverse and emerging approaches to achieve successes in this exciting field.
Arthur G. Cook (ZS Associates) publishes 2nd Edition with Gower
The eagerly awaited second edition of Arthur G. Cook's Forecasting for the Pharmaceutical Industry is now available from Gower.
Forecasting for the Pharmaceutical Industry is a definitive guide for forecasters as well as the multitude of decision makers and executives who rely on forecasts in their decision making.
In virtually every decision, a pharmaceutical executive considers some type of forecast. This process of predicting the future is crucial to many aspects of the company - from next month's production schedule, to market estimates for drugs in the next decade. The pharmaceutical forecaster needs to strike a delicate balance between over-engineering the forecast - including rafts of data and complex ‘black box’ equations that few stakeholders understand and even fewer buy into - and an overly simplistic approach that relies too heavily on anecdotal information and opinion. Arthur G. Cook's highly pragmatic guide explains the basis of a successful balanced forecast for products in development as well as currently marketed products. He explores the pharmaceutical forecasting process; the varied tools and methods for new product and in-market forecasting; how they can be used to communicate market dynamics to the various stakeholders; and the strengths and weaknesses of different forecast approaches.The text is liberally illustrated with tables, diagrams and examples.The final extended case study provides the reader with an opportunity to test out their knowledge.
The second edition has been updated throughout and includes a brand new chapter focusing on specialized topics such as forecasting for orphan drugs and biosimilars.
Arthur G. Cook is a Principal with ZS Associates, a management consulting firm specializing in the pharmaceutical industry. Previously he was Director of Global Forecasting for Syntex Pharmaceuticals. Art has been involved in pharmaceutical forecasting for over 30 years, has worked with many major pharmaceutical companies on their forecasting processes, and has created forecasts for over 150 therapy areas. He has written and presented widely on the subject of forecasting, portfolio management, market research, and pricing for the pharmaceutical industry.
For further information about the book's content and to read a sample chapter or to order, please follow this link http://www.gowerpublishing.com/isbn/9781472460110. Our website gives 10% online discount as standard. If you are interested in bulk purchase, please telephone our sales department on +44 (0)1252 736600.
LAUNCH OF UNIQUE COGNITIVE ASSESSMENT TOOL MYCQPRO TO HELP TRANSFORM MENTAL FITNESS OF BRITISH WORK FORCE
Scientifically designed cognitive evaluation programme to boost cognitive health
and help cut £26bn annual cost of mental health issues to business
MyCognition, the UK’s leading provider of cognitive health technologies, today announces the launch of MyCQPro, a unique assessment tool using patent–pending technology, which evaluates cognitive health and allows individuals to monitor their mental wellbeing. The unique combination of psychometric tests in MyCQPro is set to play a disruptive role in reducing the cost of mental ill-health to UK businesses, which currently totals £26bn annually.
An OECD report, released earlier this month, estimates that, at any one time, 1 in 5 individuals of working age suffer from a mental health problem, with 70 million working days lost annually due to poor mental health. The report also calls for a shift in policy to focus on intervention in the workplace, with emphasis on improving toolkits for managers to enable preventative action.
Businesses are increasingly aware that employee’s mental fitness is as important as their physical health and are seeking to introduce effective wellbeing strategies but are struggling to measure their impact: a 2013 survey by a leading international healthcare consultancy found that only 36% of employers globally are able to measure effectively the outcomes of their health programs.
MyCQPro addresses this evaluation issue and allows individuals to identify their cognitive strengths and assess their progress in improving their cognitive health. Following initial soft launch trials, MyCognition is already working in the financial services sector to meet this wellbeing challenge, and is also in talks with a variety of blue-chip professional services businesses.
MyCQProcan be used by all businesses to address a range of areas including:
·Stress resilience for staff, to enhance retention and productivity;
·Absenteeism and medical claims, through regular cognitive assessment and timely interventions, which strengthen mental coping mechanisms;
·Team cohesion, by identifying the right cognitive mix, and improving performance when integrated with cognitive training;
·Improved leadership, by identifying areas that need strengthening and harnessing cognitive training to give managers the best chance for success
MyCQPro can be carried out from any computer or iPad, is self-administered and only takes 15-minutes. It is a unique cognitive evaluation tool, which maps an individual’s strengths in the five core cognitive domains, which together make up over 90% of our mental activity: working memory, episodic memory, attention, executive function and psychomotor speed. MyCQPro quantifies the extent of cognitive improvement, whether this is as a result of taking one of MyCognition’s training programmes or due to other interventions.
MyCQPro is based on validated and respected tests in the field of neuroscience refined over 200-years of research into the human brain. This unique cognitive evaluation tool, as well as MyCognition’s other products, has been developed in partnership with world-class institutions including the University of Cambridge and Amsterdam Medical Centre, and results from its trials have been endorsed by the Federation of European Neuroscience Societies (FENS).
Research in neuroscience has shown strong links between cognitive domains, such as working memory and executive function, with problem solving ability and strategic planning respectively, both key areas for business. Enhanced executive function can help management more effectively execute non-routine activities, such as mergers and acquisitions and strategic reviews. Firms can also use MyCQPro to help create more cohesive working teams with the right cognitive balance between more creative and more process, delivery driven individuals.
MyCQPro,and MyCognition’s stimulating and interactive training programmes developed with BAFTA-award winning company Preloaded, provide a unique mix of assessment and training in the workplace. This can deliver tangible benefits for businesses, as the programme allows employees to exercise areas in need of development and consolidate existing strengths, which improves stress resilience and strengthens mental coping mechanisms.
This helps to address presenteeism, lost productivity due to employees attending work while suffering from illness, often due to mental health issues. Combating presenteeism was cited in an established global survey of employers as the main motivation for European employers to improve their wellbeing strategies. In the UK, official figures from the Parliamentary Office for Science and Technology put the cost to companies of reduced productivity due solely to mental ill-health at over £15bn each year.
Businesses are increasingly recognising that they need a holistic Employee Value Proposition, covering both mental and physical health – an emphasis that is becoming clearer in employee benefit packages that are starting to include alternative health elements to help limit the damage caused by mental health issues. MyCQPro is a unique new addition to such packages, providing companies and employees with actionable information about their cognitive health and, when combined with MyCognition’s training programmes, gives businesses a validated method to improve the mental wellbeing of their workforce.
Duncan Knight, CEO of MyCognition, commented:
“Businesses are increasingly aware that their employees’ mental fitness is as important as their physical health. Improving cognitive health is vital to enhancing workplace wellbeing and MyCQPro can be a key part of a company’s Employee Value Proposition and holistic wellbeing strategy. In conjunction with MyCognition’s training programmes, it could also help British businesses tackle the £26bn bill they are paying due to employee mental wellbeing issues. Improving employees’ cognitive functions, such as working memory, episodic memory, attention and executive function, decreases stress in employees, reduces absenteeism and helps boost productivity.”
The discount expires this Friday for CreateHealth's Customer Experience (CX) in Health Summit, May 12 London.
On May12th CreateHealth.io will define a clear methodology and share proven tactics used to develop customer centric services that improve patient outcomes.
Here's a snap shot: · Learn to support customers across multiple touch points to drive behaviour change and product ROI. You will learn how making small changes to language, images and functionality (based on customer feedback) will increase engagement to your services and improve email open rates.
· Speakers include:
Rod Willmott,CIO, LV Martin Bellingham, Head of Customer Insight, AXA Andrew Hancock, Head of Customer Services & Revenue Management, EDF Energy Marc Barlow, Head of Global Strategic Marketing, GE Healthcare Alan How, Head of Devices and Digital. Health Commercial Excellence and Business Intelligence Department, Merck Serono Rachel Jones, Global Publications Manager, Pharmacist, AstraZeneca
· Join 100 pharma colleagues + CX leaders from outside Healthcare. With attendees already registered from GSK, Pfizer, Merck, AZ, Sanofi, GP's, European payers, IDF, RBS, AXA, GE...
Secure your discount of £200 & register for only £595 by clicking here:http://createhealth.io/cx/register/
Media Contact: Kate Eversole Director, Marketing firstname.lastname@example.org | +44 (0) 779 6844 655 | createhealth.io